Absence of acute cocaine interactions with the MAO-B inhibitor selegiline

Kathleen A. Haberny; Sharon L. Walsh; David H. Ginn; Jeffery N. Wilkins; Jane E. Garner; David Setoda; George E. Bigelow

doi:10.1016/0376-8716(95)01137-N

Absence of acute cocaine interactions with the MAO-B inhibitor selegiline

Kathleen A. Haberny, Sharon L. Walsh, David H. Ginn, Jeffery N. Wilkins, Jane E. Garner, David Setoda, George E. Bigelow

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Selegiline, an irreversible monoamine oxidase-B (MAO-B) inhibitor, is under investigation as a treatment for cocaine relapse prevention. To evaluate its safety, human volunteers (n = 5) received intravenous cocaine (0, 20 and 40 mg, 1 h apart) following treatment with placebo or selegiline (10 mg, p.o.). Cocaine increased heart rate, blood pressure, pupil diameter and subjective indices of euphoria and craving. Selegiline produced no measurable effects, except for miosis, and did not alter the effects of cocaine. These data suggest that selegiline may be safely administered in combination with cocaine, and that selegiline is unlikely to increase reinforcing effects of cocaine.

Original language	English
Pages (from-to)	55-62
Number of pages	8
Journal	Drug and Alcohol Dependence
Volume	39
Issue number	1
DOIs	https://doi.org/10.1016/0376-8716(95)01137-N
State	Published - Jul 1995

Funding

Funders	Funder number
National Institute on Drug Abuse	K05DA000050

Keywords

Cardiovascular
Cocaine
Safety
Selegiline
Subjective
l-Deprenyl

ASJC Scopus subject areas

Toxicology
Pharmacology
Psychiatry and Mental health
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0376-8716(95)01137-N

Cite this

@article{d52ee028ac2b4b27afa43408aa4c6ed2,

title = "Absence of acute cocaine interactions with the MAO-B inhibitor selegiline",

abstract = "Selegiline, an irreversible monoamine oxidase-B (MAO-B) inhibitor, is under investigation as a treatment for cocaine relapse prevention. To evaluate its safety, human volunteers (n = 5) received intravenous cocaine (0, 20 and 40 mg, 1 h apart) following treatment with placebo or selegiline (10 mg, p.o.). Cocaine increased heart rate, blood pressure, pupil diameter and subjective indices of euphoria and craving. Selegiline produced no measurable effects, except for miosis, and did not alter the effects of cocaine. These data suggest that selegiline may be safely administered in combination with cocaine, and that selegiline is unlikely to increase reinforcing effects of cocaine.",

keywords = "Cardiovascular, Cocaine, Safety, Selegiline, Subjective, l-Deprenyl",

author = "Haberny, {Kathleen A.} and Walsh, {Sharon L.} and Ginn, {David H.} and Wilkins, {Jeffery N.} and Garner, {Jane E.} and David Setoda and Bigelow, {George E.}",

year = "1995",

month = jul,

doi = "10.1016/0376-8716(95)01137-N",

language = "English",

volume = "39",

pages = "55--62",

number = "1",

}

TY - JOUR

T1 - Absence of acute cocaine interactions with the MAO-B inhibitor selegiline

AU - Haberny, Kathleen A.

AU - Walsh, Sharon L.

AU - Ginn, David H.

AU - Wilkins, Jeffery N.

AU - Garner, Jane E.

AU - Setoda, David

AU - Bigelow, George E.

PY - 1995/7

Y1 - 1995/7

N2 - Selegiline, an irreversible monoamine oxidase-B (MAO-B) inhibitor, is under investigation as a treatment for cocaine relapse prevention. To evaluate its safety, human volunteers (n = 5) received intravenous cocaine (0, 20 and 40 mg, 1 h apart) following treatment with placebo or selegiline (10 mg, p.o.). Cocaine increased heart rate, blood pressure, pupil diameter and subjective indices of euphoria and craving. Selegiline produced no measurable effects, except for miosis, and did not alter the effects of cocaine. These data suggest that selegiline may be safely administered in combination with cocaine, and that selegiline is unlikely to increase reinforcing effects of cocaine.

AB - Selegiline, an irreversible monoamine oxidase-B (MAO-B) inhibitor, is under investigation as a treatment for cocaine relapse prevention. To evaluate its safety, human volunteers (n = 5) received intravenous cocaine (0, 20 and 40 mg, 1 h apart) following treatment with placebo or selegiline (10 mg, p.o.). Cocaine increased heart rate, blood pressure, pupil diameter and subjective indices of euphoria and craving. Selegiline produced no measurable effects, except for miosis, and did not alter the effects of cocaine. These data suggest that selegiline may be safely administered in combination with cocaine, and that selegiline is unlikely to increase reinforcing effects of cocaine.

KW - Cardiovascular

KW - Cocaine

KW - Safety

KW - Selegiline

KW - Subjective

KW - l-Deprenyl

UR - http://www.scopus.com/inward/record.url?scp=0029146589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029146589&partnerID=8YFLogxK

U2 - 10.1016/0376-8716(95)01137-N

DO - 10.1016/0376-8716(95)01137-N

M3 - Article

C2 - 7587975

AN - SCOPUS:0029146589

SN - 0376-8716

VL - 39

SP - 55

EP - 62

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

IS - 1

ER -

Absence of acute cocaine interactions with the MAO-B inhibitor selegiline

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this